Coronary disease & ACSRandomised controlled trial
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial
- Randomised controlled trial
- open-label
- prematurely terminated
Authors' conclusion
Exploratory analyses of secondary safety endpoints, including bleeding type ≥2 and ≥3 according to the Bleeding Academic Research Consortium scale, revealed that, compared to clopidogrel and in-hospital aspirin, treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications.
Study context
- Population
- Patients with AF and ACS154 female
- Participants
- 602 patients
- Comparison
- Potent P2Y12 inhibitor vs Clopidogrel
- Primary endpoint
- Efficacy: recurrent ischemic events; safety: death and major bleeding (separate win-loss ratio analyses)
- Follow-up
- 6 weeks after randomization
Primary result
As reported in the abstract
- Trial prematurely terminated owing to safety concerns raised by the DSMB; primary results not reported in the abstract
Safety
BARC bleeding type ≥2 and ≥3 (exploratory secondary safety endpoints)
- Higher bleeding rates with potent P2Y12 inhibitor vs clopidogrel and in-hospital aspirin, without a clear reduction in ischemic complications
- exploratory analyses
Original publication
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial. Nat Med. Published 29 August 2026. doi:10.1038/s41591-026-04629-7
Summarised from the published abstract; every number is checked against it